The aim of the present study was to examine the relationships between ambulatory blood pressure (ABPM) and urinary albumin excretion (UAE) in diabetic (non-insulin dependent [NIDDM] and insulin-dependent [IDDM]) hypertensives at baseline and after treatment by an angiotensin converting enzyme (ACE) inhibitor. After a 3-week placebo period, patients were treated for 16 weeks with trandolapril, 2 to 4 mg/day. The UAE and blood pressure (mercury sphygmomanometer and 24-h ABPM) were measured at baseline and repeated on trandolapril. Predictive factors of abnormal UAE (24-h UAE > >30 mg) were determined using univariate and multivariate analysis (logistic regression). Predictors of UAE decrease were also searched. One hundred seventyone patients entered the analysis. Conversely, office BP level was not significantly related to UAE. On treatment, office BP levels decreased to 143 ؎ ؎ 13/82 ؎ ؎ 8 mm Hg (P < < .0001) and 24-h BP levels to 134 ؎ ؎ 17/78 ؎ ؎ 9 mm Hg (P < < .0001). In the abnormal UAE group, UAE significantly decreased from 76 to 50 mg/day (P ‫؍‬ ‫؍‬ .006). After treatment, independent predictive factors of abnormal UAE were: on-drug fasting plasma glucose (OR ‫؍‬ ‫؍‬ 3.5, CI ‫؍‬ ‫؍‬ 1.7 to 7.4, P ‫؍‬ ‫؍‬ .0009) and on-drug nighttime diastolic BP (OR ‫؍‬ ‫؍‬ 3.5, CI ‫؍‬ ‫؍‬ 1.7 to 7.4, P ‫؍‬ ‫؍‬ .001). The only predictor of UAE decrease was a 24-h systolic BP decrease (OR ‫؍‬ ‫؍‬ 2.3, CI ‫؍‬ ‫؍‬ 1.3 to 4.3, P ‫؍‬ ‫؍‬ .007). We conclude that in diabetic hypertensives with abnormal UAE, trandolapril exhibited a sustained 24-h antihypertensive effect and provided a consistent reduction of microalbuminuria. This study confirmed the superiority of ABPM over clinical BP to predict target organ damage. Am J
H ypertension is frequently observed in diabetic patients. 1, 2 The relationship between hypertension and diabetes is complex. Hypertension is closely associated to the extent of renal injury and might aggravate several complications of diabetes such as coronary disease, arteriopathy, retinopathy, and nephropathy. 3 Microalbuminuria is considered as an initial sign of glomerular injury in normotensive and hypertensive diabetic patients, 4, 5 as well as in patients with essential hypertension. 6, 7 In diabetes mellitus, microalbuminuria has been shown as a predictor of the progression of nephropathy, 8 but also of cardiovascular morbidity and mortality. 8, 9 In essential hypertension, microalbuminuria has been positively correlated with markers of the severity of hypertension such as blood pressure level 6 or target organ damage. 10 Hypertensive patients with microalbuminuria could exhibit a higher prevalence of cardiovascular disease. 11, 12 Several trials using different antihypertensive agents have been conducted in microalbuminuric patients with either essential hypertension or diabetes mellitus. Previously, it has been reported that angiotensin converting enzyme (ACE) inhibitors could be superior to other antihypertensives in reducing urinary albumin excretion. 13 ACE inhibitors could exhibit a beneficial renoprotective effect on glomerular function and structure beyond that obtained by blood pressure reduction alone. 14 Blood pressure levels are usually evaluated by repeated measurements with mercury sphygmomanometer but they might be influenced by the phenomenon of white coat hypertension. 15 Ambulatory blood pressure monitoring is a well-established method that allows the determination of circadian variations of blood pressure and the efficacy of antihypertensive treatment. 16 Moreover ambulatory blood pressure monitoring has been found to be more closely related to target organ damage 17, 18 and to cardiovascular mortality, 19, 20 than casual blood pressure. The aim of this study was to examine at baseline the relationships between ambulatory blood pressure and urinary albumin excretion (UAE) in diabetic hypertensive patients and to evaluate whether treatment by an angiotensin converting enzyme (ACE) inhibitor could modify this relationship.
METHODS

Patients
Men and women aged 18 to 75 years with mild to moderate hypertension and diabetes mellitus were eligible to enter the study. At the end of a 3-week placebo run-in period, office diastolic blood pressure (DBP) had to be confirmed in the range 90 to 115 mm Hg. Ambulatory blood pressure levels at baseline were not used as inclusion criteria. Main exclusion criteria were 1) any serious chronic disease, 2) known hypersensitivity or contraindication to ACE inhibitors, 3) serum creatinine Ͼ150 mol/L, and 4) concomitant antihypertensive medications. All patients gave their written informed consent and the protocol was approved by the Comité Consultatif de Protection des Personnes se prêtant à la Recherche Biomédicale of Toulouse, France.
Study Design
This was an open multicenter study. After a 3-week placebo run-in period, eligible patients received trandolapril 2 mg once daily for 16 weeks. After 4 weeks of treatment, the dosage had to be increased to 4 mg once daily in nonresponder patients. If patients were still nonresponders at 8 weeks, 20 mg of furosemide had to be added to 4 mg of trandolapril.
Blood Pressure Measurements
Office blood pressure was recorded both at the end of the placebo run-in period (to check that inclusion criteria had been met), after 4 and 8 weeks of treatment, and at the end of the active treatment period. Physicians were recommended to perform three consecutive measurements in the sitting position after a 10-min rest using a mercury sphygmomanometer. Systolic blood pressure (SBP) was defined by phase I and DBP by phase V Korotkoff sound. At each evaluation, the mean of three readings defined office SBP and DBP. Patients were defined as nonresponders if the DBP was Ͼ90 mm Hg or the DBP decreased by Ͻ10 mm Hg.
Ambulatory 24-h blood pressure monitoring (ABPM) was performed both at the end of the placebo period and at the end of the active treatment period. Ambulatory recordings were made using the SpaceLabs 90207 monitor (Redmond, WA). Four measurements per hour were programmed during both day and night. Diastolic blood pressure values greater than SBP values, DBP values lower than 40 mm Hg or more than 150 mm Hg, SBP values lower than 60 mm Hg or more than 250 mm Hg, and values with differential arterial pressures less than 10 mm Hg were excluded. 21 Mean hourly BP was calculated as the average of the measurements in the clock-range Ϯ 30 min. Recordings with less than 75% of hourly means available were discarded. Average SBP and DBP levels were determined for each of the following periods: 24h, daytime (7 am to 10 pm) and nighttime (10 pm to 7 am). Patients were defined as nondippers if the ratio of daytime BP level minus nighttime BP level over daytime BP level was Ͻ10% for both SBP and DBP. 20 The prevalence of hypertension based on ambulatory monitoring was calculated using the threshold value of 139/87 mm Hg for 24-h BP. 22 Therefore, patients with 24-h BP Յ139/87 mm Hg were considered as white coat hypertensives.
UAE Measurements
Urinary albumin excretion was measured both at the end of the placebo period and at the end of the active treatment period. At each time point, a single 24-h urine collection was done. After completion, volumes were measured and aliquots of urine were taken from the 24-h collection. Thereafter, urine aliquots were sent to a central laboratory for dosage. UAE was measured by immunonephelometry. The high sensitivity and reproducibility of this method has been previously reported. 23 Urinary creatinine was also measured to ensure adequacy of UAE measurements. Normoalbuminuria was defined as 24-h UAE Ͻ30 mg, microalbuminuria as 24-h UAE ranging from 30 to 299 mg, and macroalbuminuria as 24-h UAE Ն300 mg. Fasting blood samples were drawn and sent to central laboratory for measurement of glycosylated hemoglobin (HbA 1c ) using HPLC and for standard chemical tests (serum creatinine, kaliemia, serum glucose).
Statistical Analysis Data were expressed as mean Ϯ SD. As UAE did not follow a normal distribution, it was expressed by its median and the 5th and 95th percentiles. Subjects were categorized as having normoalbuminuria (0 to 29 mg/day) or abnormal UAE (Ն30 mg/day). Differences between the two groups were compared using Student's t test for quantitative variables and 2 test for qualitative variables (univariate analysis). Multivariate logistic regression analysis was used to estimate the independent association of abnormal UAE with selected clinical variables (age, gender, body mass index, duration of hypertension and diabetes, complications), blood pressure levels (office and ambulatory BP), and biological parameters (serum creatinine, fasting serum glucose, and HbA 1c ). These analyses were performed at baseline and after treatment. Predictive factors of UAE decrease were also analyzed by both univariate and multivariate analyses. They were described by their odds ratio (OR) and corresponding 95% confidence intervals (CI). Statistical significance was considered for P Ͻ .05. SAS statistical software (V6.08) (Cary, NC) was used for all calculations.
RESULTS
One hundred seventy-one patients (mean age 62 Ϯ 10 years, 54% men), with valid ABPM and UAE dosages, completed the study. Noninsulin-dependent diabetes was present in 95% of patients and insulin-dependent diabetes in 5%. At baseline, mean office BP was 164 Ϯ 14/97 Ϯ 6 mm Hg and 24-h BP was 142 Ϯ 17/83 Ϯ 10 mm Hg. Forty-five patients (26%) were classified as ambulatory hypertensives and 126 patients (74%) as white coat hypertensives.
Ninety-seven patients (57%) had normoalbuminuria and 74 patients (43%) exhibited UAE Ն30 mg/24 h. Among them, 65 patients (38%) had microalbuminuria and 9 patients (5%) exhibited macroalbuminuria. Univariate analysis compared the characteristics of patients with normoalbuminuria at baseline to those of patients with abnormal UAE (Table 1) . According to this analysis, significant predictive factors of abnormal UAE at baseline were: known diabetes duration, retinopathy, degree of metabolic control as determined by HbA 1c , and ambulatory BP levels. Nondipping was significantly more frequent in patients with abnormal UAE. In white coat hypertensives, median UAE was lower than in ambulatory hypertensives (44 mg/day v 22 mg/day, P ϭ .008). Conversely, age, sex, body mass index, hypertension duration, and office blood pressure were not significantly related to baseline UAE level. In the multivariate analysis (Table 2) , only three factors emerged as independent predictive factors of abnormal UAE: nighttime DBP, retinopathy, and diabetes duration. Nighttime DBP was the first predictive factor: patients with nighttime DBP Ն75 mm Hg had a fourfold increased risk of abnormal UAE compared to patients having nighttime DBP Ͻ75 mm Hg (P Ͻ .0001). Presence of retinopathy multiplied the risk by 3 (P ϭ .047) and duration of diabetes Ն5 years doubled this risk (P ϭ .025).
At the end of the 16-week treatment period, 120 patients (70.2%) were still on 2 mg of trandolapril, 34 patients (19.9%) on 4 mg of trandolapril, and 17 patients (9.9%) were receiving 4 mg of trandolapril and 20 mg of furosemide. There was no difference in treatment distribution between the normoalbuminuric group and the abnormal UAE group.
After 16-week treatment mean office BP levels decreased to 143 Ϯ 13/82 Ϯ 8 mm Hg (P Ͻ .0001) and 24-h BP level to 134 Ϯ 17/78 Ϯ 9 mm Hg (P Ͻ .0001). On-drug office and ambulatory BP level of patients according to UAE at baseline are shown in Table 3 . Baseline and on-drug circadian BP levels of both groups are represented in Figures 1 and 2 . In the two groups, office and ambulatory BP decreased significantly. However, on-drug ambulatory BP levels still remained higher in the abnormal UAE group when compared to the normoalbuminuric patients (all P Ͻ .05).
In the normoalbuminuric group, UAE increased slightly although the median was unchanged. In the abnormal UAE group, UAE significantly decreased from 76 to 50 mg/day (P ϭ .006). Among normoalbuminuric patients at baseline, 12 patients (12%) exhibited UAE Ն30 mg/day on trandolapril. Conversely, 21 patients (28%) with abnormal UAE at baseline recovered normoalbuminuria (P ϭ .0002). Univariate analysis compared the characteristics of patients with normoalbuminuria on treatment to those of patients with abnormal UAE on treatment (Table 4) . According to this analysis, significant predictive factors of abnormal UAE on treatment were: diabetes duration, retinopathy, degree of metabolic control as determined by on-drug HbA 1c and fasting serum glucose, on-drug 24-h, daytime, nighttime SBP and DBP levels. In white coat hypertensives, UAE levels still remained lower when compared to ambulatory hypertensives (33 v 20 mg/day, P ϭ .01). On-drug office SBP level was also 
No between-group difference was observed for BP decrease (Student's t-test).
UAE change was significantly different (P ϭ .0001) between the two groups (Wilcoxon test).
Abbreviations as in Table 1 . AJH-SEPTEMBER 1998 -VOL. 11, NO. 9 associated with abnormal UAE. After multivariate analysis, only two factors emerged as predictive factors of abnormal UAE on trandolapril: on-drug fasting serum glucose and on-drug nighttime DBP (Table 5) . Patients with on-drug fasting serum glucose Ն8 mmol/L had a 3.5-fold increased risk of abnormal
FIGURE 1. Circadian variations of blood pressure in patients with abnormal urinary albumin excretion (UAE): systolic (SBP) and diastolic (DBP) blood pressures at baseline and after treatment.
FIGURE 2. Circadian variations of blood pressure in normoalbuminuric patients: systolic (SBP) and diastolic (DBP) blood pressures at baseline and after treatment.
UAE compared to patients with serum glucose Ͻ8 mmol/L (P ϭ .0009). On-drug nighttime DBP multiplied also the risk by 3.5 (P ϭ .001).
Predictive factors of UAE changes were searched. Patients were divided into two groups according to UAE change : group 1 patients with UAE decrease (n ϭ 82) and group 2 patients with no change in UAE or UAE increase (n ϭ 89). Univariate analysis showed the following potential predictive factors of UAE decrease: 24-h SBP (P ϭ .007), daytime SBP (P ϭ .078), daytime DBP (P ϭ .078), and HbA 1c changes (P ϭ .09). After multivariate analysis, the only predictive factor of UAE decrease was 24-h SBP decrease; patients with a 24-h SBP decrease of Ͼ7.5 mm Hg were more likely to present with an UAE decrease when compared to patients with a 24-h SBP decrease Յ7.5 mm Hg (OR ϭ 2.3, CI 95% ϭ 1.3 to 4.3, P ϭ .007).
DISCUSSION
The relationship between blood pressure levels and urinary albumin excretion in hypertensive diabetic patients has been studied in several trials. Office blood pressure levels have been inconsistently found to be higher in microalbuminuric patients when compared to those of normoalbuminuric patients. However, casual blood pressure has been found to be less closely related to microalbuminuria than ambulatory blood pressure. Bianchi et al 24 have found a significant correlation between UAE and 24-h SBP but no significant correlation was present between UAE and office blood pressure. Palatini et al 25 have compared office and ambulatory BP level among 53 microalbuminuric subjects and 744 normoalbuminuric; office BP levels were slightly higher in the microalbuminuric group, but this increase was only significant for DBP. Ambulatory SBP and DBP levels were found more significantly higher in the microalbuminuric group. Using logistic regression analysis, only 24-h SBP emerged as a predictive factor of overt microalbuminuria. Our study confirms that ambulatory BP is more strongly associated with abnormal UAE. These results are in accordance with previous studies showing that target organ damage and cardiovascular mortality correlate better with average 24-h blood pressure than with casual office blood pressure. [17] [18] [19] [20] A significant number of either hypertensive or diabetic patients fail to manifest the normal nocturnal decrease of blood pressure. They have been called nondippers. Several studies have shown that nondippers exhibit greater evidence of organ damage and a higher incidence of cardiovascular morbidity and mortality. 20 Indeed these patients showed a higher prevalence of overt microalbuminuria as compared to nondippers. 24,26 -28 In our study the phenomenon of nondipping was more frequently found in patients with abnormal UAE. However, the level of nocturnal DBP seems to be more relevant than the daytime/ Abbreviations as in Table 1 .
AJH -SEPTEMBER 1998 -VOL. 11, NO. 9 nighttime blood pressure difference. At baseline, using multivariate analysis, nighttime DBP was the first predictive factor of abnormal UAE, whereas nondipping disappeared when adjusted for the other independent risk factors. This major role of nighttime blood pressure has been previously reported by Berrut et al. 26, 29 Apart from ambulatory BP factors, our study revealed that duration of diabetes and presence of retinopathy were weaker predictors of abnormal UAE. Known diabetes duration has been previously correlated with UAE in one study, 30 but this relationship is not usually found. Relationships between abnormal UAE and clinical target organ damage, such as retinopathy 30, 31 and peripheral vascular disease, 31, 32 have been more consistently reported. In insulin-dependent diabetes mellitus (IDDM) patients, microalbuminuria is usually consequent to poor glycemic control and renal vascular lesions due to diabetes. 33 In non-insulin-dependent diabetes mellitus (NIDDM) hypertensive patients, microalbuminuria can be attributed to diabetic glomerular lesions or to essential hypertension associated with diabetes. The results of this study support that diabetes control and duration can be important determinants for microalbuminuria in hypertensive NIDDM patients, in addition to coexisting hypertension. Other clinical variables, such as age, male gender, or body mass index, have been inconsistently reported, 11,31 but were not found in our study. Trandolapril is a long-acting ACE inhibitor. Several studies using ABPM have demonstrated a sustained BP decrease over 24 h and beyond. 34, 35 Its trough-topeak ratio is constantly more than 50%. It has been demonstrated to provide a longer duration of action than other well-established ACE inhibitors such as enalapril 36 and perindopril. 37 This study confirms a true 24-h antihypertensive effect. However, because of the large number of ambulatory normotensive patients at baseline, the magnitude of blood pressure reduction was modest.
After 4 months of treatment, in the overall population, a slight but not significant decrease in the number of patients with abnormal UAE was observed. These results are mainly explained by the low prevalence of abnormal UAE at baseline. However, in the group of patients with abnormal UAE, a significant decrease on both median of UAE and number of microalbuminuric patients was found. These results are in accordance with those previously reported with either trandolapril 38 or other ACE inhibitors. 39 This study is the first one aiming to evaluate the predictive factors of abnormal UAE after treatment by an ACE inhibitor. The only two predictors were ondrug fasting serum glucose and on-drug nighttime DBP. Nocturnal blood pressure remained the most important predictor among ambulatory BP variables.
However, its importance decreased after treatment, whereas diabetes metabolic control emerged as the first predictor. These results can be explained by the antihypertensive effect of trandolapril, which has decreased the ambulatory BP levels in most of the patients. Indeed, 24-h SBP decrease was the only independent determinant for UAE decrease. In the Diabetes Control and Complications Trial (DCCT) it has been shown that intensive treatment of insulindependent diabetes reduced the risk of diabetic complications including microalbuminuria. This was attributed to improved glycemic control, but the relationship between the degree of hyperglycemia and the risk of microalbuminuria was not examined. 40 In a recent study the relationship between microalbuminuria and quality of diabetes glycemic control evaluated by glycated hemoglobin has been highlighted. 41 In our study, the impact of poor glycemic control emerged when blood pressure was decreased by the treatment; poor metabolic control rather than an insufficient ambulatory BP control was the reason for persistent microalbuminuria in these patients.
In conclusion, in diabetic hypertensive patients with abnormal UAE, trandolapril exhibited a sustained 24-h antihypertensive effect and provided a consistent reduction of microalbuminuria. Independent risk factors for abnormal UAE were nighttime DBP, diabetes duration, and presence of retinopathy. After treatment, on-drug nighttime DBP was still a predictor of persistent UAE but fasting serum glucose emerged as the most important predictor. Moreover, the 24-h SBP decrease was the only independent determinant for UAE decrease. This study confirms the superiority of ambulatory blood pressure (especially nighttime blood pressure) over clinical blood pressure to predict target organ damage.
